Robert W. Baird Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $32.00

Dyne Therapeutics (NASDAQ:DYN) had its price target decreased by Robert W. Baird from $46.00 to $32.00 in a research report report published on Wednesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other equities research analysts also recently issued reports on the company. Oppenheimer began coverage on Dyne Therapeutics in a research note on Monday, June 2nd. They issued an “outperform” rating and a $34.00 price objective for the company. BMO Capital Markets began coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price objective for the company. Chardan Capital reissued a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday. Scotiabank began coverage on Dyne Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective for the company. Finally, JPMorgan Chase & Co. reduced their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.93.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $10.32 on Wednesday. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $47.45. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -2.87 and a beta of 1.16. The company has a 50 day moving average price of $11.60 and a 200 day moving average price of $14.59.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Equities analysts forecast that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in DYN. Caitong International Asset Management Co. Ltd lifted its position in shares of Dyne Therapeutics by 378.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock worth $32,000 after buying an additional 2,446 shares during the last quarter. Quarry LP bought a new position in shares of Dyne Therapeutics in the first quarter worth about $47,000. GF Fund Management CO. LTD. bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $50,000. E Fund Management Co. Ltd. increased its stake in shares of Dyne Therapeutics by 16.2% in the first quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company’s stock worth $144,000 after purchasing an additional 1,923 shares during the period. Finally, Optimize Financial Inc bought a new position in shares of Dyne Therapeutics in the first quarter worth about $154,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.